<
AI
Automation
Science
Innovation
Open Source
Blockchain
Social Media
Startups
Culture
Cloud
>

Destination

2025-11-14

Weight-Loss Drug Zepbound Is Being Tested as a Treatment for Long Covid

GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties can help alleviate symptoms of long Covid. [...]

Discover Copy
Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination

2025-05-30

How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 115.71

Destination

2025-01-03

The best smart scales for 2025

The New Year is here and there’s no better time to kickstart those health and fitness goals. Whether you’re looking to shed a few holiday pounds, track your muscle gains or simply stay on top of a [...]

Match Score: 105.06

Destination

2025-05-12

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 96.31

Destination

2025-04-02

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed.Read more... [...]

Match Score: 57.85

Destination

2025-09-23

YouTube may reinstate channels banned for spreading covid and election misinformation

Channels once banned by YouTube for spreading false information regarding the COVID-19 pandemic or the 2020 election may soon have the opportunity to get their channels back, in a decision transparent [...]

Match Score: 57.55

Destination

2025-04-01

Eli Lilly is coming after makers of copycat versions of Zepbound

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and Zepbound.Read more... [...]

Match Score: 54.64

Destination

2025-12-01

Eli Lilly cuts cost of Zepbound vials in weight loss drug price war's latest salvo

The announcement came just weeks after rival Novo Nordisk cut prices for cash buyers of its top-selling weight loss drugs Ozempic and Wegovy [...]

Match Score: 52.14

thenextweb

2025-01-10

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 51.59

venturebeat

2025-12-01

AI models block 87% of single attacks, but just 8% when attackers persist

One malicious prompt gets blocked, while ten prompts get through. That gap defines the difference between passing benchmarks and withstanding real-world attacks — and it's a gap most enterprise [...]

Match Score: 50.32